Early catheter ablation after stroke in atrial fibrillation: a signal from observational data

Design

Target trial emulation using retrospective multicentre data (cloning-censoring-weighting)

Population

431 patients with atrial fibrillation and prior ischaemic stroke, 207 with early ablation; median follow-up 3.0 years

Primary outcome

Major adverse cardiovascular events

Effect

At 36 months: +1.54 event-free months (95% CI 0.40 to 2.85); absolute risk reduction 11.17% (95% CI 5.81 to 17.36)

Researchers used a target trial emulation to compare early catheter ablation (within a one-year grace period) with medical therapy in patients with atrial fibrillation and a history of ischaemic stroke. The data came from six Chinese centres between 2019 and 2024. A total of 431 patients were included, median age 70 years, 37% women, and 207 had early ablation. Median follow-up was 3.0 years.

At 36 months, early ablation was associated with 1.54 more months free of major adverse cardiovascular events (95% CI 0.40 to 2.85) and an absolute risk reduction of 11.17% (95% CI 5.81 to 17.36). Cardiovascular rehospitalisation was lower by 11.98 percentage points. In a matched subset of 250, ablation was associated with better modified Rankin scores (adjusted OR 0.31, 95% CI 0.19 to 0.51) and, in a post hoc analysis, lower odds of cognitive impairment on the AD8 (0.42, 0.24 to 0.72).

The design is retrospective, and patients selected for ablation are usually fitter, so residual confounding is likely. The authors classify this as Class III evidence and call for randomised trials. Anticoagulation for stroke prevention remains the established treatment.

• Continue oral anticoagulation as indicated after stroke with atrial fibrillation; this study does not alter that.
• Consider discussing rhythm-control options, including ablation, with cardiology in suitable patients with symptoms or recurrent episodes.
• Record functional status and cognition when referring; fitness shapes who is offered ablation.
• Do not quote the cognition or mRS results as proven benefit; they came from matched, partly post hoc analyses.

Why it matters

It raises rhythm control as a possible stroke-recovery strategy rather than only a symptom-control one, which randomised trials can now test.

Don't overread it

This is retrospective observational data with likely residual confounding; the authors grade it as Class III evidence and it does not change guidelines.

The statistics, in plain English

An absolute risk reduction of 11.17% means roughly 11 fewer patients per 100 had a major event by 36 months in the emulated comparison. In observational data this can be inflated if healthier patients were the ones offered ablation. The cloning-censoring-weighting method reduces, but does not remove, that bias.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.